Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;53(3-4):359-69.
doi: 10.1093/ilar.53.3-4.359.

Cancer epigenetics: a brief review

Shama Virani, Justin A Colacino, Jung H Kim, Laura S Rozek
Review

Cancer epigenetics: a brief review

Shama Virani et al. ILAR J. 2012.

Erratum in

  • ILAR J. 2013;54(1):63. Virani, Shami [corrected to Virani, Shama]

Abstract

Cancer is a disease that results from the successive accumulation of genetic and epigenetic alterations. Despite intense study, many unanswered questions about the nature of the contribution of epigenetic changes to carcinogenesis remain. In this review, we describe principles of epigenetics as they relate to our current understanding of carcinogenesis. There are a number of in vivo models of specific pathways of carcinogenesis that are very useful for the characterization of epigenetic mechanisms that link environmental exposures or genetic susceptibility and cancer progression. Because epigenetic alterations are thought to be reversible, they offer great promise for treatment of cancer. The use of animal models to evaluate the effects of decitabine and zebularine has elucidated the mechanisms of action and indicated the potential for these types of treatment. Ultimately, the greatest challenge lies in the integration of laboratory and epidemiologic data to best prevent and treat this deadly disease.

Keywords: cancer; chromatin; epigenetics; histones; mechanisms; methylation.

PubMed Disclaimer

References

    1. Allan J, Hartman PG, Crane-Robinson C, Aviles FX. 1980. The structure of histone H1 and its location in chromatin. Nature 288:675–679 - PubMed
    1. Alvarez-Nunez F, Bussaglia E, Mauricio D, Ybarra H, Vilar M, Lerma E, de Leiva A, Matias-Guiu X. 2006. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16:17–23 - PubMed
    1. Amatori S, Bagaloni I, Donati B, Fanelli M. 2010. DNA demethylating antineoplastic strategies: A comparative point of view. Genes Cancer 1:197–209 - PMC - PubMed
    1. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics 30:41–47 - PubMed
    1. Bachmann PS, Piazza RG, Janes MN, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, Cazzaniga G, Biondi A, Miranda-Saavedra D, Gottgens B, Saffery R, Craig JM, Marshall GM, Gambacorti-Passerini C, Pimanda JE, Lock RB. 2010. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia and its reversal by histone deacetylase inhibition. Blood 116:3013–3022 - PubMed

Publication types